Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
med-mastodon.com is one of the many independent Mastodon servers you can use to participate in the fediverse.
Medical community on Mastodon

Administered by:

Server stats:

416
active users

med-mastodon.com: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.7

#Wegovy

0 posts0 participants0 posts today
Public
DrBob, Neurologist, 🧠Mechanic

New Review and Meta-Analysis confirms weight gain with discontinuance of #Semaglutide and #Tirzepatide

Discontinuing GLP1 medications led to a pooled overall mean weight regain of 9.69 kg (or about 22 lbs in patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.

Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to #Obesity.

#wegovy #ozempic #mounjaro #zepbound
onlinelibrary.wiley.com/doi/10

Text Shot: Summary Research on Glucagon-like peptide 1 receptor agonist (GLP-1RA) has mainly focused on the efficacy of weight loss and not the long-term efficacy of weight loss maintenance. This systematic review and meta-analysis aims to evaluate the sustainability of weight loss of patients taking GLP-1RAs following the discontinuation of the drug. EBSCOhost was used to simultaneously search Academic Search Premier, CINHAL Ultimate, Cochrane Central Register of Controlled Trials, MEDLINE with full text, Cochrane Database of Systematic Reviews, and separate PubMed search was systematically investigated using a predetermined search strategy from inception to February 1st, 2024. The authors extracted data regarding body weight change from baseline on treatment and off treatment, change in waist circumference from baseline on and off treatment, and change in BMI from baseline on and off treatment. Meta-analysis was conducted using RevMan (version 5.4) to calculate pooled mean…
Public
DrBob, Neurologist, 🧠Mechanic

GLP-1s Are Crazy Effective — Just Not Cost-Effective

I’ll make the argument that the most effective drugs in the past decade are the GLP-1 receptor agonists, drugs like semaglutide and tirzepatide. At least in terms of weight loss, they are truly unparalleled. They are clearly effective. But are they worth it? Are they cost-effective? That is a much harder question, and, as you’ll see in a minute, despite their amazing effects, the answer — for now, at least — is no.

#mounjaro #ozempic #zepbound #wegovy #glp1
medscape.com/viewarticle/glp-1

Medscape · GLP-1s Are Crazy Effective — Just Not Cost-EffectiveBy F. Perry Wilson, MD, MSCE
Public
Научно-Технический·LAB-66

A drug that claims to cure obesity is taking over the market and people’s minds. Is semaglutide a miracle or a dangerous trap? It was made for diabetics, but now everyone’s using it—without asking what the real price might be. Some say it’s the new radium, once hyped as a cure-all. While celebrities show off their weight loss, scientists keep finding new side effects. So, is it really worth it?

lab66.substack.com/p/ozempic

#ozempic#wegovy#obesity
Public
Brittany Trang

The system "was built to keep us sick and stuck," telehealth company Hims says in a Super Bowl ad (over Childish Gambino's "This Is America"!)

But experts point out that the ad uses criticism of companies "selling weight loss drugs...to then themselves sell weight loss drugs."

via @STAT
statnews.com/2025/01/28/super-

STAT · 'Incredibly irresponsible': Hims Super Bowl ad downplays risks of compounded drugsA multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded weight loss drugs.
#health#healthcare#medicine
Replied in thread
Public
Cataplasme

@John_Livingston je sais que ça répond pas vraiment à la question mais juste un témoignage. Mon compagnon aurait pu être un candidat à la chirurgie bariatrique mais a été orienté vers le traitement #Wegovy + activité physique adaptée, et ça a super bien fonctionné pour lui. Gros gros pb, il avait eu le Wegovy en accès précoce mais ce n’est plus remboursé en ce moment (Et c’est très cher) … mais on a bon espoir que ça change au vu des bénéfices apportés . Ça peut valoir le coup d’attendre un peu?

ExploreLive feeds
About